Considering that the experiments were performed using triple-negative breast cancer, but based on the correlations we observed between the expression of ATIC and the survival outcome of HER2-positive breast cancer, the targeted ATIC products may be more toxic to HER2-positive breast cancer. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.